Aclaris Therapeutics (ACRS) Current Assets (2014 - 2026)

Aclaris Therapeutics' Current Assets history runs 13 years deep, the most recent figure standing at $110.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 1.32% year-over-year to $110.2 million; the TTM figure through Mar 2026 stood at $110.2 million (up 1.32% YoY), while the FY2025 annual figure was $96.3 million, down 23.53% from the prior year.
• Current Assets was $110.2 million for Q1 2026 at Aclaris Therapeutics, up from $96.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $259.4 million in Q2 2022 to a low of $96.3 million in Q4 2025.
• Historically, Current Assets has averaged $149.4 million across 5 years, with a median of $128.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Current Assets surged 41.92% in 2022, then slumped 52.03% in 2023.
• A 5-year view of Current Assets shows it stood at $231.6 million in 2022, then plunged by 44.35% to $128.9 million in 2023, then slipped by 2.25% to $126.0 million in 2024, then declined by 23.53% to $96.3 million in 2025, then increased by 14.45% to $110.2 million in 2026.
• The last three Current Assets figures came in at $110.2 million (Q1 2026), $96.3 million (Q4 2025), and $100.6 million (Q3 2025), per Business Quant data.